Newscast – Page 95 – media

China’s Adagene raises $50M to take anticancer antibodies into the clinic

Sequoia China has powered Adagene to a $50 million series C round. The investment positions the Chinese antibody discovery shop to move the most advanced assets in its oncology pipeline into human testing.
- Source: FierceBioTech
- 618
- March 30, 2018
Clinical Trials Company Insights oncology
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review

Bristol-Myers Squibb Company (BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo (nivolumab) plus Yervoy (ipilimumab) to treat intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). The FDA also previously granted Breakthrough Therapy Designation for this application, which is the 2nd indication for which the Opdivo plus Yervoy combination has received this designation.
- Source: drugdu
- 596
- March 29, 2018
FDA MBS New Approvals Opdivo
Bluebird Bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

Bluebird Bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.
- Source: investor.bluebirdbio
- 472
- March 29, 2018
bb2121 Celgene multiple myeloma T cell therapy
Charity launches biometrics wristband project for autistic people

The North-West charity aims to build the world’s first autism assessment and diagnostic centre in Wirral, where biometric technology will be used to measure physiological properties of people with autism.
- Source: MedicalPlasticsNews
- 609
- March 29, 2018
autism digital health Researches wearables
Conservative estimates of EHR safety incidents belie bigger industry concerns

Researchers and patient safety advocates have often warned about the association between EHR usability and patient harm, but hard numbers have been difficult to pin down.
- Source: FierceHealthcare
- 536
- March 29, 2018
digital health EHR Researches
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer
- Source: finance.yahoo
- 618
- March 28, 2018
Allergan Amgen biosimilar herceptin New Approvals
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting -Pivotal Monotherapy Phase 2 Trial Initiation Planned for 2017-

Astellas and Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed in multiple solid tumors including mUC, ovarian cancer, and non-small cell lung cancer (NSCLC). Based on the data from the ongoing phase 1 clinical trial, the companies this year plan to initiate a registrational monotherapy phase 2 trial for locally advanced or mUC patients who have been previously treated with checkpoint inhibitor (CPI) therapy. A trial evaluating enfortumab vedotin in combination with CPIs is also planned for later this year as part of a broad clinical development program.
- Source: newsroom.astellas.us
- 553
- March 28, 2018
Astellas monotherapy mUC Seattle Genetics
Novartis sells stake in joint venture to GSK for $13bn

Novartis has sold its stake in its consumer health joint venture with GlaxoSmithKline to its British rival for $13bn in an early move by Vas Narasimhan, the Swiss pharmaceuticals group's new boss, to focus on its core business.
- Source: Financial Times
- 527
- March 28, 2018
Company Insights healthcare pharmaceutical company
Improving health literacy is in pharma’s interests

Patients who understand the information provided about their health are more likely to adhere to a medicine regime and feel empowered to take steps towards healthier lifestyles. To what extent are pharma companies taking the initiative? Amanda Barrell reports.
- Source: PharmaPhorum
- 716
- March 28, 2018
Consumer Healthcare Market Views
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System™ (ADAPT) significantly out-performed standard HER2 testing in predicting response to trastuzumab (Herceptin®) for breast cancer patients.
- Source: Carislifesciences
- 869
- March 27, 2018
breast cancer Researches trastuzumab

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.